Evolution of costs of cancer drugs in a Portuguese hospital

Peixoto, Vânia

doi:10.5306/wjco.v5.i2.164

Cited by 1 publication

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Medical care cost, which accounted for 13.7% of the overall cost in 2002, was about third of the cancer burden in this study. This rapid increase is owed to an increase in cancer incidence, new indications for treatment with previously approved cancer drugs and to placement of new drugs on the market (Mariotto et al, 2011;Sullivan et al, 2011;Wani et al, 2013;Peixoto et al, 2014). Emerging trends of substituting surgeries with noninvasive/low-toxicity approaches and conventional radiotherapy with IMRT may also have driven up the medical care costs.…”

Section: Discussionmentioning

confidence: 99%

The Economic Burden of Cancer in Korea in 2009

Kim

Park

Kang

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Cancer imposes a significant economic burden on individuals, families and society. The purpose of this study was to estimate the economic burden of cancer using the healthcare claims and cancer registry data in Korea in 2009. Materials and Methods: The economic burden of cancer was estimated using the prevalence data where patients were identified in the Korean Central Cancer Registry. We estimated the medical, non-medical, morbidity and mortality cost due to lost productivity. Medical costs were calculated using the healthcare claims data obtained from the Korean National Health Insurance (KNHI) Corporation. Non-medical costs included the cost of transportation to visit health providers, costs associated with caregiving for cancer patients, and costs for complementary and alternative medicine (CAM). Data acquired from the Korean National Statistics Office and Ministry of Labor were used to calculate the life expectancy at the time of death, age-and gender-specific wages on average, adjusted for unemployment and labor force participation rate. Sensitivity analysis was performed to derive the current value of foregone future earnings due to premature death, discounted at 3% and 5%. Results: In 2009, estimated total economic cost of cancer amounted to $17.3 billion at a 3% discount rate. Medical care accounted for 28.3% of total costs, followed by non-medical (17.2%), morbidity (24.2%) and mortality (30.3%) costs. Conclusions: Given that the direct medical cost sharply increased over the last decade, we must strive to construct a sustainable health care system that provides better care while lowering the cost. In addition, a comprehensive cancer survivorship policy aimed at lower caregiving cost and higher rate of return to work has become more important than previously considered.

show abstract

Section: Discussionmentioning

confidence: 99%